Navigation

Explore our research

EsophAGheaL (EAGLe) Consortia and Aspirin International Network (AspirIN)

2004-2020


Collection of 70,000+ biospecimens allowing biomarkers of progression and prediction for patients with esophageal disease. This has resulted in several high impact papers in Nature Genetics, Lancet Oncology and Gastroenterology. This Consortia has over 200 members.

Contacts (AspECT, BOSS and ChOPIN trials)

AspECT; octo-aspect@oncology.ox.ac.uk

BOSS; hugh.barr@glos.nhs.uk

ChOPIN; TBC

Wellcome Trust: wtccc2@well.ac.uk

 

Project Team;

AspECT; 83 PI's (in England, Scotland, Northern Ireland, Wales and Canada)

BOSS; 122 PI's (in England, Scotland, Northern Ireland and Wales)

ChOPIN; 104 PI's (in England, Scotland, Northern Ireland, Ireland, Wales, Belgium, Holland)

 

Project Funding;

AstraZeneca

Cancer Research UK

NIHR/HTA

     AspECT Trial Team, Boss Trial Team, ChOPIN Trial Team and Wellcome Trust CCC2

CRUK, AstraZeneca

Jankowski JA, Moayyedi P. Cost effectiveness of Aspirin as chemoprevention for Barrett’s esophagus: a large RCT underway in the UK (original research correspondence).  

J Natl Cancer Inst 2004;96:885-7.

Jankowski J, deCaestecker J, Harrison R, Watson P, Barr H, Attwood S, Moayyedi P. Non-steroidal anti-inflammatory drugs and oesophageal adenocarcinoma: epidemiology needs randomised trials to correct for bias.   (Short Communication)

Lancet Oncology 2006;7:8-9.

 

Leedham S, Jankowski J. The evidence base of proton pump inhibitor chemopreventative agents in Barrett’s esophagus; the good, the bad and the flawed. (review)  

Am J Gastroenterol 2007;102:21-3.

 

Das D, Ishaq S, Harrison R, Kosuri K, Harper E, deCaestecker J, Sampliner R, Attwood S,  Barr H, Watson P, Moayyedi P, Jankowski J. Management of Barrett’s oesophagus in the UK: over treated, and under biopsied but improved by a national randomised trial.   

Am J Gastroenterol 2008;103:1079-89.

 

Jankowski J, Hunt R. Cyclooxygenase-2 inhibitors in colorectal cancer prevention; better the devil you know. (review)

Cancer Epidemiology Biomarkers & Prevention 2008;17:1858-61.

 

Jankowski J, Attwood S, de Caestecker J, Barr H. Aspirin in the primary prevention of vascular disease.

Lancet 2009;374:877-8.  

 

Jack Cuzick, Florian Otto, John A Baron, Powel H Brown, John Burn, Peter Greenwald, Janusz Jankowski, Carlo La Vecchia, Frank Meyskens, Hans Jörg Senn, Michael Thun. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement.

Lancet Oncol 2009;10:501-7.

 

Obszynska J, Atherfold P, Nanji M, Glancy D, Santander S, Graham T, Otto W, West K, Harrison R, Jankowski JA. Long term proton pump induced hypergastrinaemia does induce lineage-specific restitution but not clonal expansion in benign Barrett's Esophagus in vivo.

Gut 2010;59:156-63.

 

Moayyedi P, Jankowski JA. Does long term aspirin prevent cancer?                   

Brit Med J. 2010;22;341:c7326.

 

Jankowski J, Barr H, deCaestecker J, Watson P, Attwood S, Moayyedi P. Aspirin in the prevention of cancer. (Short Communication)

Lancet 2011;377:1649-50.

 

Jankowski J, Barr H, Moayyedi P. Does aspirin really reduce the risk of colon cancer? (Short Communication)

Lancet  2012 Apr 28;379:1586-7.

 

Su Z, Gay LJ, Strange A, Palles C, Lescai F, Nanji M, Sasieni P, Howarth K, Trudgill N, Tucker A, Langford C, Edkins S, van de Winkel A, Peppelenbosch MP, van der Laan LJW, Kuipers EJ, Drenth J, Peters W, Reynolds J, Kelleher D, McManus R, Grabsch H, Prenen H, Bisschops R, Krishnadath KK, Siersema P, van Baal J, Middleton M, Gillies R, Petty R, Burch N, Bhandari P, Paterson S, Edwards C, Penman I , Vaidya K, Ang Y, Murray I, Tawil A, Morris D, Nwokolo C, Isaacs P, Rodgers C, Ragunath K, Macdonald C, Haigh C, Monk D, Davies G, Wajed S, Johnston D, , Gibbons M, Cullen S, Church N, Deloukas P, Hunt S, Gray E, Dronov S, Simon Potter,  Anderson Mark, Avazeh Tashakkori-Ghanbaria, Blackwell JM, Bramon E, Brown MA, Casas JP, Corvin A, Duncanson A, Markus HS, Mathew CG, McCarthy MI, Palmer CNA, Plomin R, Rautanen A, Sawcer SJ, Trembath RC, Viswanathan AC, Wood NW, Trynka G, Wijmenga C, Cazier JB, Nicholson A, Gellatly NL, Glancy D,, Cooper S, Prew S,  Hapeshi J, Ferry D, Rathbone B,  Brown Julia, Love S, Brooks C, Attwood S, Watson P, Sanders S, Harrison R, Moayyedi P, deCaestecker J, Barr H,  Stupka E, Peltonen L, Spencer CCA, Tomlinson I, Donnelly P,  Jankowski JA*. Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett’s esophagus.

Nat Genet 9 September 2012;44:1131-6.

 

Sanders DS, Grabsch H, Harrison R, Bateman A, Going J, Goldin R, Mapstone N, Novelli M, Walker MM, Jankowski J; on behalf of the AspECT trial management group and trial principal investigators. Comparing virtual with conventional microscopy for the consensus diagnosis of Barrett's neoplasia in the AspECT Barrett's chemoprevention trial pathology audit.

Histopathology 2012;30. doi: 10.1111/j.1365-2559.2012.04288.x.

 

Jankowski JA, Satsangi J. Barrett's Esophagus: Evolutionary Insights From Genomics

Gastroenterology 2013;144:667-9.

 

Cuzick J, Thorat MA, Bosetti C, Brown PH, Burn J, Cook NR, Ford LG, Jacobs EJ, Jankowski JA, La Vecchia C, Law M, Meyskens F, Rothwell PM, Senn HJ, Umar A.

Estimates of benefits and harms of prophylactic use of aspirin in the general population.

Ann Oncol. 2015;26:47-57.

Palles C, Chegwidden L, Li X, Findlay JM, Farnham G, Castro Giner F, Peppelenbosch MP, Kovac M, Adams CL, Prenen H, Briggs S, Harrison R, Sanders S, MacDonald D, Haigh C, Tucker A, Love S, Nanji M, deCaestecker J, Ferry D, Rathbone B, Hapeshi J, Barr H, Moayyedi P, Watson P, Zietek B, Maroo N, Gay L, Underwood T, Boulter L, McMurtry H, Monk D, Patel P, Ragunath K, Al Dulaimi D, Murray I, Koss K, Veitch A, Trudgill N, Nwokolo C, Rembacken B, Atherfold P, Green E, Ang Y, Kuipers EJ, Chow W, Paterson S, Kadri S, Beales I, Grimley C, Mullins P, Beckett C, Farrant M, Dixon A, Kelly S, Johnson M, Wajed S, Dhar A, Sawyer E, Roylance R, Onstad L, Gammon MD, Corley DA, Shaheen NJ, Bird NC, Hardie LJ, Reid BJ, Ye W, Liu G, Romero Y, Bernstein L, Wu AH, Casson AG, Fitzgerald R, Whiteman DC, Risch HA, Levine DM, Vaughan TL, Verhaar AP, van den Brande J, Toxopeus EL, Spaander MC, Wijnhoven BP, van der Laan LJ, Krishnadath K, Wijmenga C, Trynka G, McManus R, Reynolds JV, O'Sullivan J, MacMathuna P, McGarrigle SA, Kelleher D, Vermeire S, Cleynen I, Bisschops R, Tomlinson I, Jankowski J. QPolymorphisms near TBX5 and GDF7 are associated with increased risk for Barrett's esophagus.

Gastroenterology. 2015;148:367-78.

1. Gharahkhani P, Fitzgerald RC, Vaughan TL, Palles C, Gockel I, Tomlinson I, Buas MF, May A, Gerges C, Anders M, Becker J, Kreuser N, Noder T, Venerito M, Veits L, Schmidt T, Manner H, Schmidt C, Hess T, Böhmer AC, Izbicki JR, Hölscher AH, Lang H, Lorenz D, Schumacher B, Hackelsberger A, Mayershofer R, Pech O, Vashist Y, Ott K, Vieth M, Weismüller J, Nöthen MM; Barrett's and Esophageal Adenocarcinoma Consortium (BEACON); Esophageal Adenocarcinoma GenEtics Consortium (EAGLE); Wellcome Trust Case Control Consortium 2 (WTCCC2), Attwood S, Barr H, Chegwidden L, de Caestecker J, Harrison R, Love SB, MacDonald D, Moayyedi P, Prenen H, Watson RG, Iyer PG, Anderson LA, Bernstein L, Chow WH, Hardie LJ, Lagergren J, Liu G, Risch HA, Wu AH, Ye W, Bird NC, Shaheen NJ, Gammon MD, Corley DA, Caldas C, Moebus S, Knapp M, Peters WH, Neuhaus H, Rösch T, Ell C, MacGregor S, Pharoah P, Whiteman DC*, Jankowski J*, Schumacher J* (* joint senior authors). Genome-wide association studies in oesophageal adenocarcinoma and Barrett's oesophagus: a large-scale meta-analysis.
Lancet Oncol. 2016 Aug 12. pii: S1470-2045(16)30240-6.

Clarifying genomics of common diseases such as Barrett’s esophagus and cancer, supporting aspirin chemoprevention studies to identify the risk-benefit ration of low dose aspirin in preventing cancer and providing evidence for better cancer prevention and gastric acid suppressing agents.